Fosamac 150mg Injection
Rx RequiredSalt Composition: Fosaprepitant Dimeglumine
Expiry Date: 01/2028
Buy at $30.00
Inclusive of all taxes
1 Vial(s)
About The Product
Nausea and Vomiting
Description
Fosamac 150mg Injection is an antimetic medication that is used to prevent nausea and vomiting caused by the chemotherapy and cancer treatments.
It contains Fosaprepitant Dimeglumine salt that works by blocking the action of substance P, a natural substance in the brain that triggers the nausea and vomiting symptoms.
Uses
- Prevent Nausea and Vomiting
Side Effects
Like any other chemical-based medication, Fosamac 150mg Injection side effects also ranges from mild to serious. Patients are advised to seek immediate medical attention if they experience any signs of an allergic reaction, severe problems or prolonged symptoms.
- Constipation
- Headache
- Indigestion
- Heartburn
- Tiredness
- Loss of Apetite
- Hiccups
- Dizziness
- Diarrhea
- Increased Liver Enzymes
- Severe Allergic Reaction
- Unusual Bleeding
- Brusing
- Signs of Infection
- Blistering
- Severe Skin Reactions
How To Use
- Fosamac 150mg Injection is administered intravenously. It can be administered either alone or with other cancer treatment therapies.
- Patients should not self-administer; it must be injected by a doctor or trained nurse. Consult a doctor for precise dosage and timing.
How It Works
- Fosamac 150mg Injection contains Fosaprepitant Dimeglumine salt that works by blocking the action of substance P, a natural substance in the brain that triggers the nausea and vommiting symptoms.
- Aprepitant blocks the NK1 receptors in the central nervous system thus, blocking the the emetic signals triggered by substance P.
Safety Advice
FAQs
The major use of Fosamac 150mg Injection is to prevent nausea and vomiting caused due to chemotherapy in cancer treatment.
References
- Garnock-Jones, K. P. (2016). Fosaprepitant dimeglumine: a review in the prevention of nausea and vomiting associated with chemotherapy. Drugs, 76(14), 1365-1372. https://pubmed.ncbi.nlm.nih.gov/27510503/
- Colon-Gonzalez, F., & Kraft, W. K. (2010). Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert opinion on drug metabolism & toxicology, 6(10), 1277-1286. https://pubmed.ncbi.nlm.nih.gov/20795794/
- Van Belle, S. J., & Cocquyt, V. (2008). Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opinion on Pharmacotherapy, 9(18), 3261-3270. https://pubmed.ncbi.nlm.nih.gov/19040346/
- Xue, F., Liu, X., Qi, X., Zhou, J., & Liu, Y. (2023). The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review. Advances in Clinical and Experimental Medicine, 32(6), 701-706. https://pubmed.ncbi.nlm.nih.gov/37026971/
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
